HAPPY FATHER'S DAY! and $HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Elevation Oncology, Inc. (NASDAQ: ELEV)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates KNW, ELEV, CRKN on Behalf of Shareholders
ELEVATION ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Elevation Oncology, Inc. - ELEV
ELEV Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Elevation Oncology, Inc. Is Fair to Shareholders
Elevation Oncology Enters into Agreement to Be Acquired by Concentra Biosciences for $0.36 in Cash per Share Plus a Contingent Value Right
Elevation Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates
Elevation Oncology Presents Preclinical Proof-of-Concept Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025
Elevation Oncology to Present Preclinical Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025
Elevation Oncology Plunges 42% on Ending Development of Lead Drug
Elevation Oncology Stops Gastric Cancer Study, Slashes Staff By 70%
Elevation Oncology to Discontinue Development of EO-3021; Advancing EO-1022, While Evaluating Strategic Options
Elevation Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Achievements
Elevation Oncology to Participate in Upcoming Investor Conferences
Elevation Oncology Provides Updates on Differentiated ADC Programs and Upcoming Milestones
Elevation Oncology Expands Pipeline with Nomination of EO-1022, a HER3 ADC for the Treatment of HER3-expressing Solid Tumors
Elevation Oncology Licenses ADC Technology from Synaffix to Drive Pipeline Expansion
Elevation Oncology Presents Preclinical Proof-of-Concept Data Supporting Combination Potential of EO-3021 with VEGFR2 or PD-1 Inhibitors at ESMO Immuno-Oncology Annual Congress 2024
Elevation Oncology to Present at the Piper Sandler 36th Annual Healthcare Conference
Elevation Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Achievements
What Makes Elevation Oncology (ELEV) a New Strong Buy Stock
Empery Asset Management's Strategic Acquisition in Elevation Oncology
Elevation Oncology Receives Fast Track Designation from the FDA for EO-3021 for the Treatment of Adult Patients with Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Expressing Claudin 18.2
Elevation Oncology to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Undercovered Dozen: Elevation Oncology, Ivanhoe Mines, Union Pacific, Golub Capital +
Why Is Penny Stock Elevation Oncology Trading Lower On Tuesday?
Elevation Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Achievements
Elevation Oncology Announces Promising Initial Data from Phase 1 Clinical Trial Evaluating EO-3021 in Patients with Advanced Unresectable or Metastatic Solid Tumors Likely to Express Claudin 18.2
Elevation Oncology Announces Planned Combination Strategy for EO-3021 in Patients with Gastric or Gastroesophageal Junction Cancer
Elevation Oncology to Present at the Citizens JMP Life Sciences Conference
Elevation Oncology: Mid-2024 EO-3021 Data Could Get Ball Rolling
Elevation Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Achievements
Elevation Oncology: Continuing To Seek Footing As It Climbs (Rating Upgrade)
Elevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024
All Three of Our Analysts Agree
Elevation Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Achievements
Trim the Fat: 3 Overbought Stocks Poised for a Pullback
Elevation Oncology to Present Preclinical Proof-of-Concept Data for HER3-ADC Program at the American Association for Cancer Research (AACR) Annual Meeting 2024
Elevation Oncology Appoints Experienced Clinical Development Leaders Julie Cherrington, Ph.D. and Alan Sandler, M.D.
SHAREHOLDER ALERT: Kaskela Law LLC Announces Shareholder Investigation of Elevation Oncology (ELEV) and Encourages Investors to Contact the Firm
Elevation Oncology to Participate in Upcoming Investor Conferences
3 Stock Winners That Are Up 400% or More in 2024
Elevation Oncology Expands Ongoing Phase 1 Clinical Trial of EO-3021 Globally, Dosing First Patient in Japan
Elevation Oncology Announces Appointment of Darcy Mootz, Ph.D., to its Board of Directors
Elevation Oncology Announces Program Updates and Upcoming 2024 Milestones
Elevation Oncology to Present at the Piper Sandler 35th Annual Healthcare Conference
Elevation Oncology Reports Third Quarter 2023 Financial Results and Highlights Recent Business Achievements
Elevation Oncology to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Elevation Oncology Announces First Patient Dosed in the Phase 1 Clinical Trial Evaluating EO-3021
Elevation Oncology Reports Second Quarter 2023 Financial Results and Highlights Recent Business Achievements
Elevation Oncology Appoints Joseph Ferra as Chief Executive Officer and Promotes Tammy Furlong to Chief Financial Officer